The blood monocytic population, selected with anti-CD14, displayed a higher positivity for CD206 after treatment with ibrutinib in all 5 CLL patients with an increase of MFI from 37 (±4) to 49 (±45) (Figure 6A, upper panel, *P<0.05). This evidence concerns the gene MRC1 and B-cell chronic lymphocytic leukemia.